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Abstract
Lysine-specific demethylase 1 (Lsd1/Aof2/Kdm1a), the first enzyme with specific lysine demethylase activity to be described,
demethylates histone and non-histone proteins and is essential for mouse embryogenesis. Lsd1 interacts with numerous
proteins through several different domains, most notably the tower domain, an extended helical structure that protrudes
from the core of the protein. While there is evidence that Lsd1-interacting proteins regulate the activity and specificity of
Lsd1, the significance and roles of such interactions in developmental processes remain largely unknown. Here we describe
a hypomorphic Lsd1 allele that contains two point mutations in the tower domain, resulting in a protein with reduced
interaction with known binding partners and decreased enzymatic activity. Mice homozygous for this allele die perinatally
due to heart defects, with the majority of animals suffering from ventricular septal defects. Molecular analyses revealed
hyperphosphorylation of E-cadherin in the hearts of mutant animals. These results identify a previously unknown role for
Lsd1 in heart development, perhaps partly through the control of E-cadherin phosphorylation.
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Introduction
The development of the mammalian heart is a complex process
involving the coordinate interplay of numerous pathways. Because
of this, one of the most common causes of lethality in genetically-
modified mice involves heart defects [1], and congenital heart
defects affect approximately 1% of human newborns [2]. The
heart is the first organ to form during development, with
differentiation of cardiomyocytes in mice beginning at embryonic
day 7.5 (E7.5), leading to the formation of the heart tube. The
heart tube begins beating at E8.0, and by E9.0 exhibits a regular
beating rhythm [3]. The tube is composed of three layers, the
myocardial layer, the endothelial layer, and the cardiac jelly.
Recent results have demonstrated that the development of the
heart arises from two cell lineages, with the second heart field
being the source of the outflow-tract and myocardium [4]. The
heart tube loops to the right, leading to the eventual formation of
the atria and ventricles with contributions from both the first and
second heart fields. In the heart, localized ‘‘swellings’’ of the wall
appear at approximately E9.5; these are known as cushions, which
arise from the cardiac jelly, and are critical for the formation of all
septal and valvular structures of the mature heart [5]. The
developing heart is initially composed of a single ventricle;
subsequent formation of the septum, separating the ventricle into
two distinct compartments, allows for the unidirectional flow of
blood through the animal. The muscular portion of the ventricular
septum begins to appear at E11.5 [3]. The closure of the ventricles
is complete by E14.0, at which point the muscular portion, derived
from the heart wall, and the membranous portion, arising from the
cushions, have fused to form a complete separation between the
ventricles [3].
Cardiac defects are a major source of late-stage lethality during
mouse development, including improper formation of the walls
between the chambers, outflow tract malformations, and defects in
the cardiac conduction system [1]. The genetics underlying these
defects are complex, and may involve large numbers of genes [6];
approximately 80% of heart defects in human newborns occur in a
sporadic manner, with the genetics still being characterized [7].
Because of the complexity of the development of the heart, and the
lack of in vitro cellular systems that are available to model its
development, the dissection of these pathways has primarily
depended on the characterization of mutant mouse models. For
example, the initial identification of the second heart field was with
a transgenic mouse expressing lacZ under the control of the Fgf10
gene [8]. The proliferation of cardiac progenitor cells appears to
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be controlled by a complex interaction between Notch1 and b-
catenin pathways, and their effects on transcription factors such as
Isl1 [9]. Mouse models have since been used to identify many
proteins that are involved in the development of the heart
(reviewed in reference [4]). Despite this, much about the molecular
mechanisms controlling the development of the heart remains to
be clarified.
Human lysine-specific demethylase 1 (LSD1, also known as
AOF2/KDM1A) was the first of a group of enzymes with lysine-
specific demethylase activity to be characterized [10]. LSD1
contains an amine oxidase domain, which demethylates proteins
in a FAD-dependent manner, and a Swi3p, RSC8p, and Moira
(SWIRM) domain, which is a characteristic of proteins that
interact with chromatin. LSD1 exhibits enzymatic activity toward
di- and monomethyl histone H3 lysine 4 and lysine 9 (H3K4 and
H3K9, respectively); the specificity for H3K9 arises when LSD1
binds to the androgen receptor (AR), resulting in a shift of its
activity from H3K4 [11]. This highlights the key role the LSD1
binding partners have in determining its enzymatic targets. The
demethylation of H3K4 results in repression of transcriptional
activity, while the opposite occurs when H3K9 is demethylated,
indicating a context-dependent effect of LSD1 on gene expression.
This switch in specificity is aided by phosphorylation of threonine
6 of H3 by protein kinase C b 1, which interacts with the LSD1-
AR complex [12]. Several other LSD1 interacting partners have
been identified, including the CoREST, CtBP, NRD and BRAF35
complexes as well as Blimp-1 and ZNF217 and ZNF198 [13–16].
The interaction of the LSD1/CoREST/HDAC complex with
SUMO-2 is important for specific gene repression [17]. Similarly,
Myc recruits LSD1 to specific chromatin regions, where it is
required for efficient Myc-induced transcription [18]. These
interactions occur primarily through the LSD1 tower domain,
an insertion in the amine oxidase domain that extends as much as
90A˚ from the center of the protein.
The activity of LSD1 is not solely directed toward histone
proteins. For example, LSD1 demethylates p53 when it is
dimethylated at K370 [19]. This results in a loss of p53-53BP1
interaction, leading to a decrease in the promotion of apoptosis by
p53, possibly contributing to cancer progression. p53 directly
interacts with LSD1, and this interaction serves to promote LSD1
binding to and activity at specific promoters [20]. Demethylation
of E2F1 by LSD1 promotes apoptosis by stabilizing the protein,
allowing its accumulation through a mechanism involving the
inhibition of the ubiquitination of the E2F1 protein [21]. Loss of
Lsd1 in mouse embryonic stem cells results in a decrease in Dnmt1
protein levels [22], as methylation of Dnmt1 leads to its
degradation. It is likely that further studies will identify other
proteins that are the targets of LSD1 action.
We and others have generated Lsd1-null mice and demonstrat-
ed that knockout embryos die during the early stages of
development [22,23]. Further studies have begun to elucidate
the role of Lsd1 in various organ systems. Expression of Lsd1 is
required for neural stem cell proliferation, and knockdown of Lsd1
in the brain results in decreased progenitor proliferation [24].
Interestingly, alternative splicing generates brain-specific Lsd1
isoforms that affect neurite morphology [25], while in rats,
upregulation of Lsd1 expression occurs upon brain injury [26].
The interaction of Lsd1 with TAL1, as part of a larger complex, is
involved in maintaining erythroid cells in an undifferentiated state
[27]. Recent work has also established that Lsd1 is required for
adipogenic differentiation, where its activity on methylated H3K9
primes the chromatin for upregulation of key factors involved in
adipogenesis [28]. LSD1 appears to play a role in human cancer,
as it is overexpressed in tumors from several organs [29,30].
Conversely, examination of prostate cancer samples indicates
minimal expression changes of LSD1 [31]. LSD1 expression is
often decreased in human breast cancer, and ectopic expression of
this protein is sufficient to decrease metastatic ability [32]. LSD1
interaction with Snai1 is required for repression of epithelial
marker genes, and to maintain the epithelial state in cancer cells
[33,34]. In neuroblastomas, LSD1 expression is inversely corre-
lated with the differentiation state of the cells, and knockdown of
LSD1 results in defects in cellular growth in xenograft models
[35].
While many roles for LSD1 continue to be identified, its in vivo
role beyond early development remains poorly characterized. This
has been hampered in particular by the fact that the Lsd1-null
mice die in utero. We sought to take advantage of the conditional
floxed allele that was generated during the course of our previous
study [22] to explore the function of Lsd1 in specific tissues.
However, the animals homozygous for the floxed allele exhibited a
failure to survive after birth. This suggested that the floxed allele
actually represented a hypomorphic allele, and would instead
provide further insight into the role of Lsd1 during the later stages
of development. The hypomorphic animals suffered from heart
defects, identified as the likely cause of perinatal lethality. The
floxed allele contained two point mutations, which were subse-
quently shown to decrease both Lsd1 enzymatic activity and
binding to several known interactors. This resulted in the
upregulation of a small subset of gene products. In addition, E-
cadherin was hyperphosphorylated in these hearts. These results
thereby identify a novel role for Lsd1 in the proper development of
the mammalian heart.
Results
The Floxed Lsd1 Allele is Hypomorphic
Previous reports [22,23] demonstrated that embryos lacking a
functional copy of Lsd1 die early during development, at
approximately day E6.5. We therefore attempted to examine the
effect of Lsd1 knockout in specific tissues by employing the Cre-lox
technology. We sought to generate mice homozygous for the
floxed allele (Aof22lox/2lox). Genotyping of late stage embryos
demonstrated that homozygous 2lox/2lox animals could reach this
stage of development (Figure 1A). However, intercrosses of
Aof22lox/+ mice resulted in no Aof22lox/2lox animals reaching
adulthood. A closer examination of the development of these
mice indicated that at E13.5 and E18.5 the expected Mendelian
ratio was observed (Figure 1B); however, by three weeks of age no
Aof22lox/2lox mice were present. This perinatal lethality is often a
sign of a cardiovascular defect, where animals succumb following
birth due to the defective circulation of oxygenated blood [1].
Phenotypic analysis of late-stage E18.5 embryos was accom-
plished by light microscopic evaluation of tissue sections in order
to identify any potential developmental abnormalities. Of five
E18.5 Aof22lox/2lox embryos which were completely serially
sectioned and tissues subsequently evaluated by light microscopy,
three showed ventricular septal defects (VSDs) characterized by
incomplete closure of the membranous portion of the ventricular
septum (Figure 1C), and the other two showed a left atrio-
ventricular valve defect and myodegeneration/mineralization of
the heart, respectively. Similar VSDs were also identified in all
four Aof22lox/1lox pups examined (1lox = null allele). For the
Aof22lox/2lox and Aof22lox/1lox pups which were examined by light
microscopy, sectioned tissues from littermate wild-type pups served
as appropriate controls. As no major defects in other organs and
tissues were observed in Aof22lox/2lox and Aof22lox/1lox pups, we
Lsd1 and Heart Development
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Figure 1. Mice homozygous for the floxed (‘‘2lox’’) allele show heart defects. (A) Genotyping of late stage embryos. Genomic DNA was
isolated from 6 representative E18.5 embryos, and the Aof2 allele analyzed by PCR genotyping. Both the wild-type (253 bp) and 2lox (392 bp) alleles
can be observed, with two animals homozygous for the 2lox allele. The size, in base pairs, of DNA size standard markers is indicated on the left of the
image. (B) Embryos homozygous for the 2lox allele survive to birth, but die shortly thereafter, as shown by the lack of homozygous pups at day P21.
The data represents the percent of each genotype present at the indicated time point; for E13.5, this is the total of 3 litters, while E18.5 and P21
represent data from 6 pooled litters each. (C) Representative photomicrograph (H&E staining) illustrating a ventricular septal defect in an E18.5
Aof22lox/1lox pup at low magnification (upper right hand panel; 1.0x) and higher magnification (lower right hand panel; 3.0x) compared to a wild type
control animal (upper and lower left hand panels). (D) Sequence comparison of the wild-type and 2lox Aof2 alleles. Sequencing results in the regions
with the two point mutations are presented for Aof2wt and Aof22lox alleles. The corresponding base pair sequence is written above the respective
graphs. The A to G mutations at positions 1379 and 1483 (positions based on mRNA sequence) are highlighted in red, and indicated by the arrows.
doi:10.1371/journal.pone.0060913.g001
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concluded that the heart defects were primarily responsible for the
perinatal lethal phenotype.
The Floxed Allele Contains Two Point Mutations
Targeting of Aof2 generated a conditional allele with floxed
exons 10–13 [22]. The loxP sites in the Aof22lox allele are located in
the introns of the gene [22], and are not supposed to affect protein
function, so we examined whether the Lsd1 coding sequence was
altered during the generation of this allele. cDNA from wild-type
and Aof22lox/2lox mouse embryonic fibroblasts (MEFs) was cloned
and the coding sequences compared by sequencing. The sequence
of the 2lox allele was found to contain two adenine-to-guanine
point mutations (Figure 1D), which had been accidentally
introduced in the gene-targeting vector. The mutations resulted
in two amino acid changes (E413G and M448V) in the ‘‘tower’’
domain of Lsd1, which is known to mediate protein-protein
interactions [36–38], and as such could have important negative
effects on Lsd1 function. As the crystal structure of Lsd1 has been
solved [36,38,39], the predicted effect of these point mutations on
the structure and function of this protein was then modeled (Figure
S1). The amino acid at position 413 is located near the base of the
tower domain, and is in close proximity to the catalytic domain.
This could potentially affect the enzymatic activity of Lsd1 and/or
the structure of the tower domain. The mutation at 448,
conversely, occurs at a residue that plays a role in the binding
between Lsd1 and CoREST, a protein that is involved in
modulating Lsd1 activity [40], and so would be more likely to
alter protein-protein interactions. Based on these models, it is
therefore possible that the Aof22lox/2lox mice were affected by
decreased protein activity, altered protein-protein interactions, or
both.
Lsd1 Expression during Heart Development
In order to understand the regulation of Lsd1 expression during
development of the heart, wild-type embryos from timed matings
were collected at defined timepoints (E8.5– E13.5, and E18.5), and
then processed for immunohistochemistry. Staining of heart
sections with an anti-Lsd1 antibody revealed widespread expres-
sion of Lsd1 in the developing heart (Figure 2). No obvious regions
of higher or lower expression, nor any temporal regulation of
expression, were observed for Lsd1, suggesting that it has a
consistent and ubiquitous expression pattern during the develop-
ment of the heart.
The Enzymatic Activity of the 2lox Lsd1 is Altered
In order to determine the effect of the point mutations on the
enzymatic activity of Lsd1, His-tagged versions of wild-type Lsd1
and the 2lox variant, as well as proteins containing each of the
single point mutations present in the 2lox variant (E413G and
M448V), were produced in bacteria and purified by affinity
chromatography. As well, a point mutant that severely impairs
Lsd1 activity (N535A [37]) was generated as a control. Coomassie
staining demonstrated the isolation of relatively pure full-length
protein for all five variants (Figure 3A). The proteins were then
incubated with an H3K4me2 peptide substrate, and the produc-
tion of the reaction by-product hydrogen peroxide used to monitor
the enzyme kinetics (Figure 3B). The Km and kcat values were then
determined for the respective enzymes (Figure 3C). Using the ratio
of kcat/Km it was determined that the efficiency of the 2lox variant
was only 39% that of the wild-type enzyme, but considerably
higher than that of the N535A mutant (18% of wild-type
efficiency). The two single point mutants, E413G and M448V,
showed relative activity that was intermediate between the wild-
type and 2lox variants; however, the E413G mutant was
substantially less active than the M448V mutant (58% vs. 85%
of wild-type efficiency). These results demonstrate that the 2lox
Lsd1 has reduced demethylase activity, primarily due to the
mutation at amino acid 413.
The Point Mutations in 2lox Lsd1 Affect Protein-protein
Interactions
Lsd1 interacts with numerous proteins, including CoREST,
HDAC1, Zfp198, and the AR [13–16]. This could have important
consequences for Lsd1 function, as its binding partners determine
the activity of Lsd1. For example, Lsd1 demethylates H3K9 only
upon interaction with the AR [11]. Because the mutations in the
2loxLsd1 are located in the tower domain, the ability of Lsd1 to
bind to known partners was examined. Initially, complexes
containing full-length FLAG-tagged Lsd1 variants were isolated
from transiently transfected NIH 3T3 cells, and the co-
immunoprecipated proteins were identified by immunoblot. The
wild-type Lsd1 protein interacted with CoREST and HDAC1, as
did the N535A mutant, which demonstrated that the enzymatic
activity of Lsd1 is not required for binding (Figure 4A). On the
other hand, the 2lox variant of Lsd1 showed substantially reduced
binding to both proteins, indicating that the two mutations are
sufficient to alter the association of Lsd1 with interacting proteins.
This was further demonstrated by quantifying the binding of Lsd1
to CoREST (Figure 4B). The 2lox variant showed a significantly
decreased ability to interact with CoREST, compared to both the
wild-type and N535A proteins. Examination of the single point
mutants demonstrated that the M448V mutation was predomi-
nantly involved in the decrease in CoREST binding, as predicted
by the structural modeling (Figure S1).
To confirm the results in a more physiologically-relevant
system, the interaction between endogenous Lsd1 and CoREST
in primary MEFs was examined. Immunoprecipitation of
CoREST resulted in more Lsd1 being pulled down in the wild-
type MEFs compared to the 2lox/2lox MEFs. Similarly,
substantially less CoREST was co-immunoprecipitated with the
2lox Lsd1 compared to the wild-type protein (Figure 4C).
Quantification of these results (Figure 4D) confirmed the
significant difference in the interaction of Lsd1 with CoREST in
these cells. These results indicate that the ability of the Lsd1 2lox
variant to interact with its binding partners is compromised, which
most likely affects its targeting and function.
Hypomorphic Hearts Show No Major Cellular Defects
In order to attempt to determine the effect of the hypomorphic
Lsd1 allele on heart development at a cellular level, the
hypomorphic and wild-type hearts were next compared for
proliferation and cellular migration. Pregnant females (E13.5)
were injected intraperitoneally with BrdU, and then the embryos
harvested one hour later. The hearts from these mice were then
examined for proliferation and cardiomyocyte presence. BrdU
incorporation in the wild-type and Aof22lox/2lox hearts was
essentially identical (Figure S2A), indicating that the cardiac
defects were not the result of a proliferation deficiency at this stage
of development. The defect in ventricular septation may also have
resulted from defective cardiomyocyte migration [41]. Therefore,
the presence of cardiomyocytes in the developing septum of the
embryos was examined to determine if there was a change in
cellular population of this structure by staining for sarcomere
myosin (Figure S2B). However, no substantial difference in the
cardiomyocyte presence was noted between the wild-type and
hypomorphic hearts.
Lsd1 and Heart Development
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Figure 2. Lsd1 expression in the developing heart. Wild-type embryos at the indicated development stages (E8.5 to E13.5, and E18.5) were
dissected and processed for immunohistochemistry. H&E staining was performed, along with staining with anti-Lsd1 to visual the Lsd1 expression
pattern during heart development. Note that in all panels, the black bar represents 100 mm.
doi:10.1371/journal.pone.0060913.g002
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Gene Expression in the Hypomorphic Hearts
Because Lsd1 is known to modify gene expression [10,11],
microarrays were performed on RNA samples isolated from the
hearts of wild-type and 2lox/2lox littermates at developmental day
E18.5. The data from these microarrays was analyzed to identify
gene products that demonstrated significant expression changes
between the hypomorphic and control hearts, with the cut-off for
significance being an adjusted p-value of 0.05. Using these
parameters, only 36 unique gene products demonstrated signifi-
cant changes between the control and the Lsd1 hypomorphic
hearts (Table 1). Consistent with the role of Lsd1 in transcriptional
repression, the majority of the genes exhibiting alterations in their
expression levels were upregulated in the Aof22lox/2lox hearts.
Indeed, only 6 gene products were found to be downregulated,
including Lsd1 (Aof2) itself. Aside from the two point mutations, no
unintended genetic alterations were identified in the gene-
targeting vector. The reduction of the Lsd1 transcript, therefore,
could be due to the insertion of loxP sites or the point mutations,
which might affect Lsd1 transcription or processing or mRNA
stability. The reduction of Lsd1 probably did not significantly
contribute to the heart defects, as mice heterozygous for the Lsd1
null allele (1lox/+), which produce similar amount of Lsd1 as
2lox/2lox mice (Figure S3), showed no obvious phenotype [22].
In order to confirm these results, RNA samples were isolated
from hearts of E18.5 embryos for quantitative real-time polymer-
ase chain reaction (qRT-PCR) analysis. The hypomorphic hearts
showed increased expression of Calcium/calmodulin-dependent
protein kinase 2 beta isoform (CamK2b) compared to wild-type
hearts, although the extent of the increase varied greatly between
2lox/2lox animals and was not statistically significant (Figure 5A).
Figure 3. The enzymatic activity of the hypomorphic Lsd1 is reduced. (A) Coomassie blue staining of His-tagged Lsd1 proteins expressed
and purified from bacterial cells. The arrow indicates the full-length protein. (B) 10 mg of enzymes were incubated with the indicated concentrations
of substrate (H3K4me2) at room temperature. Absorption was measured at 50-sec intervals. Initial rate was obtained from linear least squares fit to
the 0–300 sec data and converted to pmol/min/ug by H2O2 standard. (C) Table demonstrating the Km, kcat and kcat/Km values for the respective Lsd1
proteins. The percentage value indicates relative activity compared to the wild-type Lsd1.
doi:10.1371/journal.pone.0060913.g003
Lsd1 and Heart Development
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The difference in mRNA levels of Fblim1, as observed by
microarray, was not recapitulated in this case, while the increase in
Tescalcin was confirmed (Figure 5A). Tescalcin, which encodes an
EF-hand calcium-binding protein, is highly expressed in the heart,
but its role, if any, in heart development is largely unknown.
Several genes known to be involved in heart development - Nkx2-
5, b-catenin, and Ncam – were also analyzed. None of them
showed obvious alterations in the hypomorphic hearts (Figure 5A).
Consistent with the microarray data, mRNA levels of Lsd1 were
decreased by approximately 50% (Figure 5A).
Despite the lack of Wnt pathway activation noted in the
microarray results (Table 1), alterations in Wnt pathway targets
were examined due to the important role this pathway has during
cardiac development [42]. Thus, the mRNA expression of Wnt11,
low density lipoprotein receptor-related protein 6 (Lrp6), Kit, and
Islet1 (Isl1), all of which are known to be targets of the Wnt
pathway, was compared between the wild-type and hypomorphic
animals. No major difference was noted in the expression of any of
the genes (Figure 5B), confirming the microarray results.
Lsd1 interacts with Snai1, which plays a role in the regulation of
epithelial-mesenchymal transition (EMT) [33]. Because the
formation of a complete ventricular septum requires, in part, that
cells undergo an EMT, we examined the expression of epithelial
and mesenchymal markers in the hypomorphic hearts. The
expression of Pecam1 and VE-cadherin, two epithelial markers,
and of UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,
polypeptide 6 (B4galt6) and Fibronectin1 (Fn1), two mesenchymal
markers, was thus determined by qRT-PCR. No significant
change in expression was noted for any of these RNAs (Figure 5C),
suggesting that EMT was not affected in the defective hearts.
Increased E-cadherin Phosphorylation in the
Hypomorphic Hearts
Because none of the genes identified by microarray were
obvious causes of the cardiac defects, a candidate approach was
employed to examine pathways involved in heart development.
Lysates were generated from E18.5 hearts and subjected to
immunoblotting (Figure 6). In agreement with the microarray and
qRT-PCR results, Lsd1 showed an approximately 50% reduction
in the hypomorphic hearts, whereas Nkx2-5, an important
transcription factor involved in heart development, was not
altered. While the expression levels of Ncam and E-cadherin,
Figure 4. The 2lox Lsd1 variant shows decreased binding to known interactors. (A) Immunoblots of FLAG-based coimmunoprecipitations
of NIH 3T3 cells transfected with the Lsd1 variants demonstrate that the 2lox protein exhibits greatly reduced complex formation with known binding
partners CoREST and HDAC1. For the two single point mutants, the M448V mutation has a more profound effect on CoREST binding. *:
immunoglobulin heavy chain. (B) The relative coimmunoprecipitation of the Lsd1 binding partner CoREST was quantitated using ImageJ software.
Data represent the mean +/2 SD for two independent experiments. (C) Purification of endogenous Lsd1 complexes from MEF lines confirmed a
decrease in Lsd1-CoREST interaction in cells expressing the mutant Lsd1. All westerns are representative of results from experiments performed in
triplicate. (D) The decrease in the endogenous interaction of Lsd1 and CoREST by the 2lox variant was quantitated, using ImageJ software. Data
represent the mean +/2 SD for three independent experiments. **: p,0.001; *: p,0.005, compared to binding by wild-type Lsd1.
doi:10.1371/journal.pone.0060913.g004
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adhesion molecules involved in heart development, did not appear
to be substantially different between the wild-type and hypomor-
phic hearts, the phosphorylation of E-cadherin (on serines 838 and
840) was significantly increased in hypomorphic hearts. We also
examined the levels of active and total b-catenin and observed no
obvious difference between wild-type and 2lox/2lox hearts
(Figure 6).
In order to confirm these results, we carried out immunohis-
tochemistry on the E18.5 wild-type and hypomorphic hearts. In
agreement with the immunoblotting data, there was a general,
major increase in the phosphorylated form of E-cadherin in the
2lox/2lox hearts compared to the wild-type animals (Figure 7A).
Phosphorylation of E-cadherin has been shown to enhance its
affinity to bind b-catenin [43,44]. Indeed, the localization of b-
catenin appeared altered in 2lox/2lox hearts, with a greater
proportion of the protein localized to the plasma membrane and a
lower amount in the cytoplasm (Figure 7B). The levels and
localization of other proteins examined, including Notch1, total E-
cadherin, Nkx2-5, and VEGF, showed no obvious differences
between wild-type and hypomorphic hearts (data not shown).
Expression of Lsd1 was similar in these animals, with a slightly
decreased strength of staining in the 2lox/2lox hearts (Figure 7C).
Staining with a non-specific IgG control antibody confirmed the
specificity of the staining (Figure 7D). Together, our results suggest
Table 1. Statistical analysis of microarray data (significant probes only).
ID geneID Symbol Alias logFC AveExpr P.Value adj.P.Val
1423327_at 68172 Rpl39l 4930517K11Rik 1.65661733 4.879415714 4.71E–09 0.000212569
1426762_s_at 99982 Aof2 1810043O07Rik|AA408884|D4Ertd478e|KDM1|LSD1|mKIAA0601 20.806952025 10.0118442 3.72E–08 0.00051495
1439231_at - - - 1.798007862 4.516676493 4.19E–08 0.00051495
1418744_s_at 57816 Tesc 1010001A17Rik|2410011K10Rik|MGC117906|TE-1 1.324826506 8.587824503 4.57E–08 0.00051495
1417461_at 12331 Cap1 CAP, ADENYLATE CYCLASE-ASSOCIATED PROTEIN 1 (YEAST) 0.940176297 9.858377389 6.21E–08 0.000560536
1426761_at 99982 Aof2 1810043O07Rik|AA408884|D4Ertd478e|KDM1|LSD1|mKIAA0601 20.830586858 8.667753279 2.34E–07 0.001761303
1424531_a_at 21401 Tcea3 S-II|SII-K1 21.499887611 6.983186765 2.96E–07 0.001906522
1437678_at 268491 Gm1564 Gm663 1.480513556 4.215117103 3.47E–07 0.001956026
1427242_at 13206 Ddx4 AV206478|Mvh|VASA 2.865609711 5.130828105 4.10E–07 0.001980549
1456515_s_at 277353 Tcfl5 AV260129|Figlb|MGC118431 1.216187744 4.392256828 4.39E–07 0.001980549
1434739_at 207854 Fmr1nb 3830422N12Rik|MGC117577|NY-SAR-35|NYSAR35 2.474837058 6.357752736 5.32E–07 0.002179904
1418743_a_at 57816 Tesc 1010001A17Rik|2410011K10Rik|MGC117906|TE-1 1.071346057 6.682441161 7.10E–07 0.002668349
1436837_at 98558 Mael 4933405K18Rik|AU019877 0.861535783 4.188648361 9.17E–07 0.003182021
1429812_at 69885 2610002D18Rik MGC169895 21.010273857 6.400725776 1.35E–06 0.00433516
1449534_at 20962 Sycp3 Cor1|Scp3 0.856261449 4.496058513 1.87E–06 0.005622336
1431393_at 75801 Six6os1 4921504I02Rik|4930447C04Rik|A930035O15Rik|Six6OS 0.630695524 4.480152174 2.28E–06 0.006424947
1449121_at 14105 Fusip1 FUSIP2|NSSR1|NSSR2|Nssr|SRrp40|TASR|TASR1|TASR2 0.762048367 7.914440868 2.92E–06 0.00774473
1438820_at 30054 RNF17 MAX DIMERIZATION PROTEIN MEMBER-INTERACTING PROTEIN 2 1.615141479 5.478954231 3.51E–06 0.008782703
1419004_s_at 12047 Bcl2a1d A1-d 0.48188309 6.573698785 8.39E–06 0.019920285
1440319_at 329207 Rbm44 Gm817 1.232361133 5.551037194 1.01E–05 0.022836103
1430591_at 13195 DDC DOPA DECARBOXYLASE 1.120828305 5.575460697 1.14E–05 0.023613271
1423418_at 110196 Fdps 6030492I17Rik|AI256750|Fdpsl1|MGC107162|mKIAA1293 20.601158533 9.261279901 1.15E–05 0.023613271
1444797_at 382231 8030474K03Rik Gm1142 1.245922269 4.636070653 1.22E–05 0.023839685
1420641_a_at 59010 Sqrdl 0610039J17Rik|4930557M22Rik 20.732545714 5.362931986 1.31E–05 0.023839685
1449141_at 74202 Fblim1 2410043F08Rik|Cal|Gt10 0.516562587 8.832495757 1.35E–05 0.023839685
1433707_at 14397 Gabra4 Gabra-4 20.757299828 5.337890838 1.37E–05 0.023839685
1416889_at 21953 Tnni2 TROPONIN I, SKELETAL, FAST 2 1.324112333 9.537045837 1.47E–05 0.024024794
1426808_at 16854 Lgals3 GBP|L-34|Mac-2|gal3 0.881798344 5.398023447 1.49E–05 0.024024794
1453133_at 73333 Slc25a31 1700034J06Rik|Ant4|Sfec 3.233037918 6.145036273 1.82E–05 0.028026024
1453444_at 70548 5730437C12Rik RIKEN CDNA 5730437C12 GENE 0.860004042 3.85174898 1.86E–05 0.028026024
1451335_at 231507 Plac8 C15|D5Wsu111e 0.932106891 4.876588334 2.08E–05 0.030318937
1437693_at 110957 D1Pas1 DNA SEGMENT, CHR 1, PASTEUR INSTITUTE 1 0.686257773 4.115476211 2.19E–05 0.030862294
1452730_at 66184 Rps4y2 1110033J19Rik|AA407494|MGC59460 0.584362686 11.13225107 2.37E–05 0.03240169
1447703_x_at 68040 Zfp593 RIKEN CDNA 3110024A21 GENE 20.803697081 6.564396628 2.44E–05 0.032423765
1455869_at 12323 camk2b CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II, BETA 1.022786929 6.570458877 2.53E–05 0.032614424
1436778_at 13058 Cybb C88302|Cgd|Cyd|Nox2|gp91phox 0.830600755 5.023893862 2.76E–05 0.034559966
Legend: ID, Affymetrix probe ID; logFC, log value of the Fold change in expression in the 2lox/2lox hearts; AveExpr, average expression in wild-type hearts;
P.value, unadjusted P-value; adj.P.Val, adjusted P-value.
doi:10.1371/journal.pone.0060913.t001
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that Lsd1 plays a role in controlling the balance of phosphory-
lation of E-cadherin in the heart.
Discussion
In this study, we have identified a previously unknown role for
the lysine demethylase Lsd1 in cardiac development in mice.
Previous reports examining Lsd1 function in vivo employed
knockout mice that showed early embryonic lethality (at approx-
imately E6.5) [22,23], thereby precluding an examination of the
contribution of Lsd1 to later stages of development. We have
characterized mice homozygous for an Aof2 allele that encodes a
hypomorphic protein containing two point mutations in the tower
domain. This Lsd1 variant exhibits reduced demethylase activity
(Figure 3) as well as decreased binding to known interacting
partners (Figure 4), although it does retain residual amounts of
both activities. The resulting mice demonstrated cardiac develop-
ment defects, primarily in the form of VSDs (Figure 1). This study
therefore establishes a role for Lsd1 during the development of the
mammalian heart.
Expression analysis of the hypomorphic Lsd1 hearts demon-
strated that only a small subset of gene products showed altered
expression in these hearts (Table 1). While Lsd1 has been shown to
play a role in both activation and repression of specific genes,
depending on the context [23], overexpression of this protein does
not result in an appreciable global decrease in H3K4 methylation
(data not shown), in contrast to the closely related Aof1/Lsd2/
Kdm1b [45]. This would appear to indicate that Lsd1 activity is
selective for specific promoters, and may explain the minor gene
expression alterations noted. None of the genes identified by
microarray are known to be critically involved in heart develop-
ment, although reports have indirectly implicated some of the
proteins. For example, Tescalcin is expressed in the developing
heart [46,47] and modulates the function of calcineurin and the
Na+/H+ exchanger Nhe1 [47–49]. Because Nhe1 [48] is a protein
that plays an important role in the differentiation of cardiomyo-
Figure 5. Changes in gene expression in the hypomorphic hearts. Expression of gene products, examined by qRT-PCR using RNA isolated
from E18.5 embryonic hearts. Data represents mean +/2 SD from 3 to 5 animals of each genotype, and was normalized such that the expression of
the mRNA in wild-type animals was equal to 1 (*: p,0.05). (A) Lsd1 mRNA levels were decreased by approximately 50%, confirming the microarray
data. Nkx2-5, a heart marker, Ncam, and b-catenin were not found to be significantly altered in the hypomorphic hearts. The expression of Tescalcin
and Fblim1, two proteins with potential roles in heart development that were identified by microarray, was also analyzed. The increase in Tescalcin
expression was recapitulated by the qRT-PCR, while no difference in Fblim1 expression between the wild-type and hypomorphic hearts was noted.
CamK2b showed minor increases in expression. (B) Expression of Wnt targets in the wild-type and hypomorphic hearts. The Wnt signaling pathway
target genes Wnt11, Lrp6, Kit, and Isl1 were examined for changes in mRNA levels in the hypomorphic hearts by qRT-PCR. No statistically significant
changes were noted in the expression of any of these genes. (C) mRNA expression of epithelial and mesenchymal markers is identical between wild-
type and 2lox/2lox hearts. Expression of the epithelial markers Pecam and VE-Cadherin, and the mesenchymal markers B4galt6 and Fn1 was
examined by qRT-PCR using RNA isolated from E18.5 embryonic hearts. No statistically significant difference was noted in the expression of any of
these mRNAs.
doi:10.1371/journal.pone.0060913.g005
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cytes [50], it is tempting to postulate that the defect noted arises
due to the overexpression of Tescalcin. However, inhibition of
Nhe1 results in decreased levels of several important cardiac
transcription factors, including Nkx2-5 [50]. Our results demon-
strated no alteration in the expression of Nkx2-5 at either the
mRNA or protein levels (Figures 5A and 6), arguing against
altered Nhe1 activity in the hypomorphic hearts. It is possible,
however, that Tescalcin acts in an Nhe1-independent pathway.
Further work is required to determine the significance of Tescalcin
upregulation in the heart defects noted in the Lsd1 hypomorphic
mice.
Because of the lack of promising proteins identified by
microarray, we undertook a candidate approach, whereby
pathways known to be involved in cardiac development were
analyzed by immunoblotting and immunohistochemistry for
alterations in the hypomorphic hearts. Among the molecules
examined was E-cadherin, which not only has a role in heart
development [51], but is a target of Lsd1-mediated transcriptional
repression [33]. Total E-cadherin levels were essentially un-
changed in the heart, but a major increase in phosphorylated E-
cadherin was noted (Figures 6 and 7), suggesting that while the
overall levels of this protein are not altered its functional state is
different.
Cell adhesion is closely regulated in the heart [52]. For example,
Ncam is expressed in a specific manner during chick heart
development [53]. Expression of the tenascin variants TNC and
TNX, which are important for tissue remodeling, also varies
greatly during heart development [54]. N-cadherin is essential for
embryonic development, with knockout animals showing heart
defects that can be partially overcome by reexpressing this protein
specifically in muscles [55]. The altered phosphorylation status of
E-cadherin in the hearts may affect cell-cell adhesion in this organ.
Phosphorylation of E-cadherin results in significantly enhanced
binding to b-catenin, by as much as 300 fold [43,44]. In breast
cancer cells, phosphorylation of b-catenin by the kinase CKIa
results in the increased formation of E-cadherin/b-catenin
complexes and increases intercellular adhesion [56]. Thus, the
increased phosphorylation of E-cadherin in the Lsd1 hypomorphic
hearts likely results in strengthened intercellular adhesion.
Immunohistochemistry analysis of the hypomorphic hearts dem-
onstrated an enrichment of b-catenin at the plasma membrane
(Figure 7B), consistent with this model. Phosphorylation of E-
cadherin is mediated, in vitro, by both GSK3b and casein kinase 2
(CK2) [44,57]. qRT-PCR analysis revealed no difference in CK2
expression levels, while GSK3b levels showed a mild decrease
(data not shown). It will be interesting to determine if Lsd1-
mediated demethylation of a non-histone target is important for
this hyperphosphorylation. Phosphorylation of E-cadherin affects
both localization and function of this adhesion molecule [58],
ultimately leading to an increase in its adhesive properties [57].
Although we did not notice a significant change in cardiomyocyte
migration into the septum (Figure S2), it is possible that the
increased adhesiveness of the phosphorylated E-cadherin inter-
feres with the final closure of the septum of the heart in the
hypomorphic animals.
Other possible mechanisms by which the Lsd1 hypomorphic
allele leads to cardiac defects can be envisaged. For example,
alterations in EMT may underlie some of the defects, including
VSDs, given that Lsd1 plays an important role in the modulation
of EMT [33] and that the development of the ventricular septum
and heart valves relies on EMT of endocardial cells. However,
several lines of evidence argue against a major defect in EMT in
Lsd1 hypomorphic animals. First, 2lox/2lox pups were able to
develop to term without major defects in other organs and tissues,
suggesting that pathways involved in EMT were largely unper-
turbed. Second, examination of the expression of epithelial and
mesenchymal markers in the hypomorphic hearts demonstrated
no appreciable difference compared to wild-type hearts
(Figure 5C). Finally, total E-cadherin protein level was not altered
in the hypomorphic hearts (Figure 6), indicating that the repressive
activity of Snai1 on E-cadherin, which requires Lsd1, was not
affected. Nevertheless, we cannot exclude the possibility that subtle
changes in EMT may have contributed to the heart defects noted
in Lsd1 hypomorphic mice.
Defects in cardiac development due to changes in gene dosage
are becoming a common observation. For example, insufficiency
in the TAB2 gene results in congenital heart defects in humans
and zebrafish [59]. In mice, the loss of a single allele of the critical
cardiac transcription factor Nkx2-5 results in heart development
defects [60]. Tbx5 insufficiency alters the expression of genes
critical for cardiac development and leads to proliferation and
migration defects [61]. The cardiac transcription factors Hand1
and Hand2 also show gene dosage effects on cardiac development,
with decreased expression leading notably to ventricular abnor-
malities [62]. Because the expression of developmental genes must
Figure 6. Protein expression in the developmentally-defective
hearts. The expression of proteins in 3 hypomorphic and 2 wild-type
control E18.5 hearts was examined by immunoblotting. A decrease in
Lsd1 and a major increase in phosphorylation of E-cadherin were noted
in the Aof22lox/2lox hearts, whereas all other proteins examined showed
no obvious changes. In the E-cadherin blot, the arrow indicates the
correct E-cadherin band, and the identity of the higher band is
unknown. The Ncam antibody recognizes the 140 kDa isoform of this
protein. Relevant molecular weight markers are indicated, in kDa, to the
right of each panel.
doi:10.1371/journal.pone.0060913.g006
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be maintained in the correct spatio-temporal pattern, it would
seem likely that epigenetic factors will play an important role in
regulating this process. Indeed, the role of epigenetic factors in
heart development has gradually been coming to light. BAF60C, a
member of the BAF chromatin remodeling complex, serves as a
bridge linking cardiac transcription factors, including Gata4, to
this complex [63]. A partial loss of BAF60C is sufficient to affect
outflow tract development; complete knockout results in even
greater defects. Similarly, the deletion of the lysine methyltrans-
ferase BOP results in defects in cardiomyocyte differentiation and
development of the right ventricle [64]. Cardiac-specific disruption
of the H3K79 methyltransferase Dot1L results in chamber
dilation, increased cardiomyocyte cell death, systolic dysfunction,
and conduction abnormalities [65]. Whole-body deletion of
HDAC2 results in perinatal lethality due to a range of heart
defects, while heart-specific deletion of HDAC1 and HDAC2 also
results in malformed hearts and death at birth [66]. This study
provides the first evidence that Lsd1 plays a key role in the final
stages of heart development in the mammalian embryo.
In summary, we have identified a role for the lysine demethylase
Lsd1 in the development of the mammalian heart, potentially
through effects on the phosphorylation of E-cadherin. Mice
Figure 7. Immunohistochemistry of the hypomorphic hearts. (A) Staining with an antibody specific for the phosphorylation of E-cadherin is
strongly increased in the Aof22lox/2lox hearts compared to the control. The arrows indicate the regions (grey for heart wall, black for septum) from
which the higher magnification images (on right) originate. (B) b-catenin localization is altered, with more of the protein present at the plasma
membrane in Aof22lox/2lox hearts. (C) Lsd1 staining shows slightly decreased signals in Aof22lox/2lox hearts. (D) Staining with a non-specific IgG control
antibody confirms the specificity of the staining. To minimize background, no counterstain was used. All photomicrographs constitute representative
fields; magnification factor is provided above or beside the photographs.
doi:10.1371/journal.pone.0060913.g007
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containing a hypomorphic variant of Lsd1 demonstrate a highly
penetrant defect in the formation of the septum separating the
ventricles. This is despite only a small number of genes that are
misregulated in the heart. Hyperphosphorylation of E-cadherin
may be sufficient to interfere with migration of the cells, leading to
the formation of VSDs. VSDs are common congenital defects in
human infants, and future work examining the status of LSD1 in
children with heart development defects will clarify the role of this
protein in human cardiac malformation.
Materials and Methods
Animal Use Ethics Statement
The mice used in these experiments, and the generation of the
Aof2 floxed allele, have been previously described [22]. All animal
procedures employed in this study were approved by the Novartis
Institutes for BioMedical Research Institutional Animal Care and
Use Committee (Protocol Number: 09 DMP 053). Genotyping of
the animals was performed using primers 440 (5’- CAG TGA
TGT ATA CCT CTC ATC AAG -3’) and 441 (5’- TAC AGA
TTT CAC TGT AAG CAT ATG -3’). The resulting bands are
392 bp for the 2lox allele, and 253 bp for the wild-type allele.
Antibodies
Antibodies used in this study were: rabbit anti-LSD1 (Cell
Signaling, 2139), mouse anti-Tubulin (Calbiochem, CP06), mouse
anti-FLAG M2 (Sigma, F 1804), mouse anti-active-b-catenin
(Millipore, 05-665), rabbit anti-phosphoS838+S840 E-cadherin
(Abcam, ab76319), rabbit anti E-cadherin (Abcam, ab53033),
mouse anti-sarcomere myosin (Developmental Studies Hybridoma
Bank, University of Iowa, MF20), mouse anti-HDAC1 (Cell
Signaling Technology #5356), rabbit anti-CoREST (Abcam,
ab32631), rabbit anti-b-catenin (Abcam, ab6302), rabbit anti-
NCAM (Cell Signaling Technology #3606), rabbit anti-mono-
methyl-Histone H3(Lys4) (Millipore, 07-436), rabbit anti-dimeth-
yl-Histone H3(Lys4) (Millipore, 07-030), rabbit anti-Histone H3
(Millipore, 07-690). Immunoblotting and immunohistochemistry
procedures were carried out employing standard protocols and
antibodies at the manufacturer’s recommended dilutions; chemi-
luminescence of immunoblots was developed using ECL-plus (GE
Life Sciences). In all immunohistochemistry experiments a
negative control was included, consisting of a non-specific rabbit
IgG antibody, to ensure the specificity of the staining (an example
is shown in Figure 7D).
Histopathology
To morphologically phenotype hypomorphic animals by light
microscopy, embryos at known developmental stages from
Aof22lox/+ intercrosses were dissected out of deciduas, and fixed
in 10% neutral buffered formalin for 24 hours. Samples were
subsequently routinely processed, embedded in paraffin, and
serially sectioned at 5.0 mm. Tissue sections were routinely stained
with hematoxylin and eosin (H&E), and then examined by bright
field light microscopy by a board certified veterinary pathologist
for any potential morphological abnormalities.
Lsd1 Cloning and Mutagenesis
Lsd1 wild-type and 2lox cDNA was generated by isolating RNA
from primary mouse embryonic fibroblast (MEF) cell lines
homozygous for the respective Lsd1 allele. Total cellular RNA
was converted to cDNA using SuperScript reverse transcriptase
(Invitrogen) and an oligo dT primer, and then the Lsd1 sequence
amplified using high-fidelity KOD polymerase (Novagen) and
specific primers (see Table S1). The amplified cDNAs were cloned
into the EcoRI-KpnI sites of the p3XFLAG-myc-CMV-26 vector
(Sigma-Aldrich) to generate FLAG-wtLsd1 and FLAG-2loxLsd1
(Note that the C-terminal myc tag would not be part of the protein
because of the presence of a stop codon in the Lsd1 cDNA). These
constructs were sequenced on both the template and complemen-
tary strands, in duplicate, to identify point mutations in the 2lox
coding sequence. Site-directed mutagenesis to generate single
point mutants employed the primers described in Table S1 and
the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The
His-tagged Lsd1 constructs were generated by subcloning the
EcoRI-SalI fragments of the corresponding FLAG-tagged con-
structs into pET-28b(+) (EcoRI partial digestion was used for the
N535A construct, because an internal EcoRI site was introduced in
the FLAG-N535ALsd1 construct). All constructs were verified by
sequencing.
Immunoprecipitations
NIH 3T3 cells were transiently transfected using Lipofectamine
2000 (Invitrogen) with vectors expressing FLAG-tagged Lsd1
variants. 48 hours later, the cells were lysed with FLAG complex
buffer (10 mM Tris, pH 8.0, 140 NaCl, 1.5 mM MgCl2, 1 mM
DTT, 0.5% Nonidet P-40, 0.1 mM NaVO4, 10 mM NaF, 10 mM
glycerol phosphate, 16protease inhibitor cocktail), and the lysate
incubated with anti-FLAG resin (Sigma-Aldrich) for 3 hours at
4uC. The beads were subsequently washed 4 times with lysis
buffer, and then resuspended in reducing SDS-PAGE sample
buffer and analyzed by immunoblot. For immunoprecipitation of
endogenous complexes, 90% confluent MEF lines were lysed with
the same lysis buffer, and pre-cleared with Protein A/G Plus beads
(Santa Cruz Biotechnology) for 1 hour at 4uC. Samples were then
left overnight with primary antibody (1:100 dilution). Protein A/G
Plus beads were added to the samples, which were left shaking at
4uC for 2 hours. The beads were then washed 4 times with lysis
buffer and resuspended in SDS-PAGE sample buffer for
immunoblotting. For changes in immunoblot intensity, films
containing bands in the linear exposure range were scanned and
analyzed by the ImageJ program (http://rsbweb.nih.gov/ij) for
relative density measurements. Statistical significance was deter-
mined using the t-test (http://www.physics.csbsju.edu/stats/t-
test_bulk_form.html).
In vitro Demethylase Assays
Wild-type and mutant Lsd1 recombinant proteins with an N-
terminal 6xHis tag were produced in E. coli and purified with
nickel affinity chromatography using standard protocols. The
demethylase activity of these proteins was tested using the LSD1
Fluorimetric Drug Discovery Kit (Enzo Life Sciences), following
the manufacturer’s instructions. Briefly, 10 mg of each Lsd1
protein (wild-type or mutant) were incubated with H3K4me2
peptide at various concentrations (0–200 mM) at room tempera-
ture, and the concentrations of hydrogen peroxide (H2O2), the
reaction product, were measured at 50-second intervals for 300
seconds. Km and Vmax values were obtained from a direct least-
squares fit to the Michaelis-Menten equation.
RNA Expression Analysis
Total RNA samples were isolated from freshly dissected E18.5
hearts using an RNeasy Plus kit (QIAGEN). RNA was then
hybridized to Affymetrix Mouse430 GeneChip. Analysis of the
results from the microarrays was performed as previously
described [67]. Briefly, statistical significance was determined
using false discovery rate corrected p-values, calculated using a
Benjamini and Hochberg correction. Corrected p-values of 0.05
were used as the cutoff for significance, corresponding to a
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significance threshold of |fold change|.1.4, adjusted p-val-
ue,0.05, using a moderated t-statistic (LIMMA). The microarray
data for this study are available with accession number GSE45583
through NCBI’s Gene Expression Omnibus (GEO).
For qRT-PCR analysis, 1 mg of total RNA was reverse
transcribed using iScript (BioRad) according to the manufacturer’s
instructions. qPCR reactions were then performed using TaqMan
Gene Expression Assays (Applied Biosystems; for primers used see
Table S2) and an ABI7500 Fast Real-Time PCR System. Relative
mRNA levels were calculated through comparison with GAPDH
amplification values.
Supplementary Information
Supplementary information is presented with this manuscript.
Supporting Information
Figure S1 Modeling of the location of the point muta-
tions in the 3D structure of Lsd1. Computer modeling of the
structure of Lsd1 indicates that the point mutation at position 413
is present at the base of the tower domain, and may have effects on
the structure of both the tower and the amine oxidase domain.
The mutation at position 448 occurs at a residue that is known to
be involved in binding to CoREST, and as such may affect Lsd1
protein-protein interactions.
(TIF)
Figure S2 Analysis of heart development in the 2lox/
2lox mice. (A) BrdU incorporation into the hearts of E13.5 mice
is similar between the wild-type and 2lox/2lox mice, indicating
that the proliferation of cells in these hearts is not altered. (B)
Staining of cardiomyocytes with sarcomere myosin antibody
(MF20) demonstrates no lack of cell colonization of the septum
in the 2lox/2lox hypomorphic hearts. No counterstain was used
for the BrdU staining, and H&E was used as a counterstain for the
MF20 staining.
(TIF)
Figure S3 Lsd1 expression in MEF cell lines. Protein
expression of Lsd1 in MEFs demonstrates similar protein
expression in heterozygous knockout and 2lox/2lox cells. The
expression levels of Lsd1 (top panel) were examined in wild-type,
heterozygous knockout (1lox/+) and homozygous hypomorphic
(2lox/2lox) MEF lines. Tubulin served as a loading control
(bottom panel).
(TIF)
Table S1 PCR primers used for cloning,sequencing and
mutagenesis in this study.
(PDF)
Table S2 Primers used for qPCR analysis in this study.
(PDF)
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